Jinguo Zhang

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Long Noncoding Rna

Transforming Growth Factor

Papillary Thyroid

Top Venues

Oxidative medicine and cellular longevity

This page only lists publications with an associated author ORCID identifier.

Publications

Shuaikang Pan, Mengting Wan, Hongwei Jin, Ran Ning, Jinguo Zhang, Xinghua Han
LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer. BMC immunology 25 (1) (2024)
Shuaikang Pan, Mengting Wan, Hongwei Jin, Ran Ning, Jinguo Zhang, Xinghua Han
LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer. BMC immunology 25 (1) (2024)
Shuaikang Pan, Mengting Wan, Hongwei Jin, Ran Ning, Jinguo Zhang, Xinghua Han
LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer. BMC immunology 25 (1) (2024)
Qingqing Sun, Jun Du, Jie Dong, Shuaikang Pan, Hongwei Jin, Xinghua Han, Jinguo Zhang
Systematic Investigation of the Multifaceted Role of SOX11 in Cancer. Cancers 14 (24) (2022)
Qingqing Sun, Jun Du, Jie Dong, Shuaikang Pan, Hongwei Jin, Xinghua Han, Jinguo Zhang
Systematic Investigation of the Multifaceted Role of SOX11 in Cancer. Cancers 14 (24) (2022)
Jinguo Zhang, Shuaikang Pan, Chaoqiang Han, Hongwei Jin, Qingqing Sun, Jun Du, Xinghua Han
Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer. Biomolecules 12 (11) (2022)
Jinguo Zhang, Xinghua Han, Lin Lin, Jian Chen, Feng Wang, Qi Ding, Li Hao, Lingyu Wang, Jie Wei, Yong Wang, Yue-Yin Pan
Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma. Oxidative medicine and cellular longevity 2022 (2022)
Jinguo Zhang, Wencai Guan, Xiaolin Xu, Fanchen Wang, Xin Li, Guoxiong Xu
A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer. Oncogene 40 (30) (2021)